Prediction of progression-free survival and risk stratification in advanced lung adenocarcinoma patients receiving EGFR-TKI therapy

Objective We aimed to investigate the clinical characteristics and computed tomography (CT) findings associated with progression-free survival (PFS) in patients with stage IIIB–IV epidermal growth factor receptor ( EGFR )-mutant lung adenocarcinoma (LAD) receiving tyrosine kinase inhibitors (TKIs) and to develop a model for PFS prediction and risk stratification. Materials and methods This retrospective study enrolled patients with stage IIIB–IV EGFR -mutant LAD who received TKI therapy and underwent pretreatment contrast-enhanced thoracic CT between January 2015 and April 2024. The Kaplan–Meier method was used to calculate the median survival time. The log-rank test was used to compare the differences in the survival curves between groups. The clinicoradiological findings associated with PFS were evaluated with a multivariate Cox regression model. The performance of the Cox regression model was assessed using the time-dependent area under the curve (AUC) and Harrell’s concordance index ( C -index). Non-parametric bootstrapping with 1,000 resamples was performed as internal validation to evaluate the robustness and discriminative ability of the model. Results A total of 242 patients (102 men and 140 women) with a mean age of 61 ± 11 years were included. The median PFS was 13 months. Multivariate analysis revealed that higher neuron-specific enolase (NSE, ≥18 ng/ml) (HR = 1.455), larger tumor size (≥5cm) (HR = 1.573), and the presence of liver metastasis (HR = 1.514) were associated with increased progression risk. On the other hand, treatment with third-generation EGFR-TKI therapy (HR = 0.694) and the presence of the vessel convergence sign (HR = 0.708) were associated with a significantly decreased risk of progression. We further constructed a nomogram based on the above five independent risk factors for predicting PFS. The C -index for predicting PFS was 0.623, and the AUCs for predicting the 6-, 12-, and 24-month PFS were 0.646, 0.676, and 0.699, respectively. The high-risk and low-risk groups were significantly different ( p < 0.001), with an HR of 1.931. The internally validated corrected global C -index was 0.610, and the AUCs for predicting the 6-, 12-, and 24-month PFS were 0.635, 0.671, and 0.695, respectively. Conclusion A nomogram based on baseline clinicoradiological factors serves as a useful tool for predicting PFS and stratifying risk in patients with advanced EGFR -mutated LAD after TKI therapy.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-19
DOI
https://doi.org/10.3389/fonc.2026.1941043
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prediction of progression-free survival and risk stratification in advanced lung adenocarcinoma patients receiving EGFR-TKI therapy

Chunju Wen, Wenjian Tang, Zhen Wu, Yuan Kang et al.
Frontiers in Oncology
Lung Cancer Treatments and Mutations
article

Prediction of progression-free survival and risk stratification in advanced lung adenocarcinoma patients receiving EGFR-TKI therapy

Chunju Wen, Wenjian Tang, Zhen Wu, Yuan Kang, Zhiqiang Zhang, Junyuan Zhong, Jiawei Feng, Haisheng Wu, Yuping Zeng
article en

Abstract

Objective We aimed to investigate the clinical characteristics and computed tomography (CT) findings associated with progression-free survival (PFS) in patients with stage IIIB–IV epidermal growth factor receptor ( EGFR )-mutant lung adenocarcinoma (LAD) receiving tyrosine kinase inhibitors (TKIs) and to develop a model for PFS prediction and risk stratification. Materials and methods This retrospective study enrolled patients with stage IIIB–IV EGFR -mutant LAD who received TKI therapy and underwent pretreatment contrast-enhanced thoracic CT between January 2015 and April 2024. The Kaplan–Meier method was used to calculate the median survival time. The log-rank test was used to compare the differences in the survival curves between groups. The clinicoradiological findings associated with PFS were evaluated with a multivariate Cox regression model. The performance of the Cox regression model was assessed using the time-dependent area under the curve (AUC) and Harrell’s concordance index ( C -index). Non-parametric bootstrapping with 1,000 resamples was performed as internal validation to evaluate the robustness and discriminative ability of the model. Results A total of 242 patients (102 men and 140 women) with a mean age of 61 ± 11 years were included. The median PFS was 13 months. Multivariate analysis revealed that higher neuron-specific enolase (NSE, ≥18 ng/ml) (HR = 1.455), larger tumor size (≥5cm) (HR = 1.573), and the presence of liver metastasis (HR = 1.514) were associated with increased progression risk. On the other hand, treatment with third-generation EGFR-TKI therapy (HR = 0.694) and the presence of the vessel convergence sign (HR = 0.708) were associated with a significantly decreased risk of progression. We further constructed a nomogram based on the above five independent risk factors for predicting PFS. The C -index for predicting PFS was 0.623, and the AUCs for predicting the 6-, 12-, and 24-month PFS were 0.646, 0.676, and 0.699, respectively. The high-risk and low-risk groups were significantly different ( p < 0.001), with an HR of 1.931. The internally validated corrected global C -index was 0.610, and the AUCs for predicting the 6-, 12-, and 24-month PFS were 0.635, 0.671, and 0.695, respectively. Conclusion A nomogram based on baseline clinicoradiological factors serves as a useful tool for predicting PFS and stratifying risk in patients with advanced EGFR -mutated LAD after TKI therapy.

Frontiers in OncologyVol. 16
Nanchang University (CN), Ganzhou People's Hospital (CN)
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon